885 related articles for article (PubMed ID: 15377287)
1. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia.
Maher L; Chant K; Jalaludin B; Sargent P
J Gastroenterol Hepatol; 2004 Oct; 19(10):1114-20. PubMed ID: 15377287
[TBL] [Abstract][Full Text] [Related]
2. Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users.
Devi KhS; Brajachand N; Singh HL; Singh YM
J Commun Dis; 2005 Mar; 37(1):73-7. PubMed ID: 16637404
[TBL] [Abstract][Full Text] [Related]
3. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia.
Miller ER; Hellard ME; Bowden S; Bharadwaj M; Aitken CK
J Infect; 2009 May; 58(5):375-82. PubMed ID: 19328555
[TBL] [Abstract][Full Text] [Related]
4. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M
BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050
[TBL] [Abstract][Full Text] [Related]
5. Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations.
Kemp R; Miller J; Lungley S; Baker M
N Z Med J; 1998 Feb; 111(1060):50-3. PubMed ID: 9539916
[TBL] [Abstract][Full Text] [Related]
6. HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran.
Rahimi-Movaghar A; Razaghi EM; Sahimi-Izadian E; Amin-Esmaeili M
Int J Infect Dis; 2010 Jan; 14(1):e28-33. PubMed ID: 19464218
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.
Maher L; Jalaludin B; Chant KG; Jayasuriya R; Sladden T; Kaldor JM; Sargent PL
Addiction; 2006 Oct; 101(10):1499-508. PubMed ID: 16968352
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C prevalence and risk behavior of injecting drug users in Sydney: a continuing concern.
Habib SE; Lovejoy FH; Aspin C
Southeast Asian J Trop Med Public Health; 2001 Dec; 32(4):823-34. PubMed ID: 12041560
[TBL] [Abstract][Full Text] [Related]
9. Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning.
Wand H; Spiegelman D; Law M; Jalaludin B; Kaldor J; Maher L
Addiction; 2009 Dec; 104(12):2049-56. PubMed ID: 19804463
[TBL] [Abstract][Full Text] [Related]
10. Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin.
Stark K; Müller R; Bienzle U; Guggenmoos-Holzmann I
AIDS; 1996 Mar; 10(3):311-7. PubMed ID: 8882671
[TBL] [Abstract][Full Text] [Related]
11. Higher HCV antibody prevalence among Indigenous clients of needle and syringe programs.
Ward J; Topp L; Iversen J; Wand H; Akre S; Kaldor J; Maher L
Aust N Z J Public Health; 2011 Oct; 35(5):421-6. PubMed ID: 21973248
[TBL] [Abstract][Full Text] [Related]
12. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study.
Ruan Y; Qin G; Yin L; Chen K; Qian HZ; Hao C; Liang S; Zhu J; Xing H; Hong K; Shao Y
AIDS; 2007 Dec; 21 Suppl 8():S39-46. PubMed ID: 18172390
[TBL] [Abstract][Full Text] [Related]
13. Irish injecting drug users and hepatitis C: the importance of the social context of injecting.
Smyth BP; Barry J; Keenan E
Int J Epidemiol; 2005 Feb; 34(1):166-72. PubMed ID: 15513970
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors.
Loebstein R; Mahagna R; Maor Y; Kurnik D; Elbaz E; Halkin H; Olchovsky D; Ezra D; Almog S
Isr Med Assoc J; 2008 Nov; 10(11):775-8. PubMed ID: 19070285
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme.
Chetwynd J; Brunton C; Blank M; Plumridge E; Baldwin D
N Z Med J; 1995 Sep; 108(1007):364-6. PubMed ID: 7566775
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of injecting drug use and associated risk behavior among regular ecstasy users in Australia.
White B; Day C; Degenhardt L; Kinner S; Fry C; Bruno R; Johnston J
Drug Alcohol Depend; 2006 Jul; 83(3):210-7. PubMed ID: 16343810
[TBL] [Abstract][Full Text] [Related]
17. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
Vicknasingam B; Narayanan S; Navaratnam V
Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis.
Judd A; Hutchinson S; Wadd S; Hickman M; Taylor A; Jones S; Parry JV; Cameron S; Rhodes T; Ahmed S; Bird S; Fox R; Renton A; Stimson GV; Goldberg D
J Viral Hepat; 2005 Nov; 12(6):655-62. PubMed ID: 16255768
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia.
Rhodes T; Platt L; Judd A; Mikhailova LA; Sarang A; Wallis N; Alpatova T; Hickman M; Parry JV
Int J STD AIDS; 2005 Nov; 16(11):749-54. PubMed ID: 16303071
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of hepatitis B and C among HIV positive patients in Georgia and its associated risk factors.
Badridze N; Chkhartishvili N; Abutidze A; Gatserelia L; Sharvadze L
Georgian Med News; 2008 Dec; (165):54-60. PubMed ID: 19124918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]